Prakt. lékáren. 2013; 9(3): 142-145

Rhinosinusitis: role and possibilities of a pharmacist; place of nasal corticosteroids

Jiří Nevrlka
Ambulance alergologie a klinické imunologie, Poliklinika Zahradníkova 2/8, Brno

Rhinosinusitis is undoubtedly among the most frequent diseases in childhood as well as adulthood. The recognition of rhinosinusitis per se is

relatively easy even in the setting of routine pharmacy service. It is the determination of the etiopathogenetic nature of this condition that

may be a challenge. For various reasons, therapeutic intervention is suitable even in the case of a seemingly mild course, particularly in

chronic rhinosinusitis. The pharmacist can choose from a wide variety of preparations and drugs that can effectively affect the course of

rhinosinusitis and bring relief from its symptoms. In addition to preparations acting nonspecifically (symptomatic preparations) characterized

rather as medical devices, some preparations affecting the course of disease and inflammatory process in a more targeted manner

(semicausal preparations), characterized rather as medications, are also available. Nasal corticosteroids are a very potent and yet very safe

drug class and can be used in essentially all types of rhinosinusitis. This class also includes drugs that can be obtained without prescription.

Keywords: rhinosinusitis, significance of rhinosinusitis, treatment of rhinosinusitis, nasal corticosteroids

Published: July 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nevrlka J. Rhinosinusitis: role and possibilities of a pharmacist; place of nasal corticosteroids. Praktické lékárenství. 2013;9(3):142-145.
Download citation

References

  1. Passali D, et al. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opinion on Drug Safety 2006; 6: 783-790. Go to original source... Go to PubMed...
  2. Seberová E. Alergická rýma. Praha: Maxdorf 2006.
  3. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids, new developments. Am J Respir Crit Care Med 1998; 157: S1-S53. Go to original source... Go to PubMed...
  4. Bielory L, et al. Position statement. Concerns about intranasal corticostroids for over-the-counter use: position statement of the Joint Task Force for the AAAAI and the ACAAI. J Alergy Clin Immunol 2006; 96: 514-524. Go to original source...
  5. Fokkens WJ. Nasal corticosteroids, first choice in moderate to severe allergic rhinitis. What prevents general practitioners from using them? Allergy 2003; 58: 724-726. Go to original source... Go to PubMed...
  6. Fokkens WJ, Lund V, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyposis. Rhinology 2007; 45(suppl 20): 1-139. - dostupný na www: <www.rhinologyjournal.com>; <www.eaaci.net>; <www.ep3os.org>. Go to PubMed...
  7. Kastner J. EP3OS - Evropský konsensus o rinosinusitidě a nosní polypóze 2007 (kapesní průvodce), Praha: Glaxo-SmithKline 2009.
  8. Brozek JL, Bousquet J, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 update J Allergy Clin Immunol 2010; 126: 466-476. Go to original source... Go to PubMed...
  9. Daley-Yates PT, Kunka RL, Yin Y, et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004; 60: 265-268. Go to original source... Go to PubMed...
  10. Delay-Yates PT, et al. Beclomethasone dipropionate: absolute bioavalability, pharmacocinetics and metabolism following intravenous, oral, intranasal and inhaled administrativ in man. Br J Clin Pharmacol 2001; 51: 400-409. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.